Logo

Exiqon Licenses miRNA Analysis Technology from Rosetta Inpharmatics

Nov 19, 2007
NEW YORK (GenomeWeb News) – Exiqon said today that it has licensed microRNA analysis technology from Merck subsidiary Rosetta Inpharmatics. 
 
The license covers real-time PCR technology used in quantitative miRNA analysis. The technology was developed for microRNA biomarker analysis at Merck.
 
Exiqon said it will use the technology in a product line for detecting miRNA that it plans to release later this year.
 
Financial terms of the agreement were not released.
 
“Being able to market quantitative real-time PCR products for miRNA analysis complements the current product offerings based on microarrays, in situ detection and knockdown products for miRNA research and expands Exiqon’s offerings for microRNA biomarker analysis,” said Exiqon CEO Lars Kongsbak.

Breaking News
The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.